CQS
BMRN icon

Credential Qtrade Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

Credential Qtrade Securities’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$858K Buy
9,827
+167
+2% +$14.9K 0.05% 162
2023
Q4 		$931K Sell
9,660
-487
-5% -$43.1K 0.06% 138
2023
Q3 		$898K Buy
10,147
+47
+0.5% +$4.18K 0.06% 137
2023
Q2 		$875K Buy
10,100
+2,682
+36% +$252K 0.06% 143
2023
Q1 		$721K Buy
7,418
+3,403
+85% +$353K 0.05% 155
2022
Q4 		$416K Sell
4,015
-52
-1% -$4.88K 0.03% 197
2022
Q3 		$345K Buy
4,067
+143
+4% +$12.7K 0.03% 191
2022
Q2 		$325K Sell
3,924
-2,715
-41% -$216K 0.02% 202
2022
Q1 		$512K Buy
6,639
+341
+5% +$28.5K 0.03% 182
2021
Q4 		$556K Buy
6,298
+86
+1% +$7.1K 0.04% 182
2021
Q3 		$480K Buy
6,212
+331
+6% +$26.1K 0.04% 179
2021
Q2 		$491K Buy
5,881
+775
+15% +$61.4K 0.04% 174
2021
Q1 		$386K Buy
5,106
+2,349
+85% +$192K 0.03% 185
2020
Q4 		$242K Hold
2,757
– – 0.03% 185
2020
Q3 		$210K Buy
2,757
+1,761
+177% +$178K 0.02% 189
2020
Q2 		$123K Buy
996
+127
+15% +$12.6K 0.02% 201
2020
Q1 		$73.4K Sell
869
-1,065
-55% -$91.8K 0.01% 194
2019
Q4 		$164K Buy
1,934
+637
+49% +$48.1K 0.02% 170
2019
Q3 		$87.4K Buy
1,297
+21
+2% +$1.62K 0.01% 187
2019
Q2 		$109K Sell
1,276
-1,102
-46% -$94.3K 0.02% 185
2019
Q1 		$211K Sell
2,378
-79
-3% -$7.32K 0.04% 157
2018
Q4 		$209K Buy
2,457
+590
+32% +$56.1K 0.05% 148
2018
Q3 		$181K Buy
+1,867
New +$186K 0.04% 169

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Credential Qtrade Securities's BMRN Position: Q1 2024 in Review

Credential Qtrade Securities increased its BioMarin Pharmaceuticals (BMRN) stake by 1.7% in Q1 2024, buying an estimated $14.9K and bringing the position to 9,827 shares worth $858K. The position accounts for 0.05% of the portfolio, ranked #162.

Credential Qtrade Securities first reported a position in BMRN in Q3 2018 and has held it in 23 quarters since. The position peaked at $931K in Q4 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Credential Qtrade Securities held 9,827 shares of BioMarin Pharmaceuticals worth $858K as of Q1 2024.
  • Credential Qtrade Securities bought 167 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $14.9K.
  • BioMarin Pharmaceuticals made up 0.05% of Credential Qtrade Securities's portfolio in Q1 2024, its #162 holding.
  • Credential Qtrade Securities first reported a position in BioMarin Pharmaceuticals in Q3 2018 and has held it in 23 quarters since.
  • Credential Qtrade Securities's BioMarin Pharmaceuticals position peaked at $931K in Q4 2023.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Credential Qtrade Securities's 13F filing for Q1 2024, filed 21 Jul 2025.